Navigation Links
Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
Date:10/18/2010

ct. 18 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present a general business overview at the Newsmakers in the Biotech Industry Conference in New York on October 22, 2010 at 10:30 a.m. EDT.

A live audio webcast and replay of this presentation may be accessed at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=TSPT&item_id=3400391 and on the Transcept Investor webpage at www.transcept.com.

About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  Transcept is also developing TO-2061, an ultra low dose ondansetron augmentation therapy for patients with obsessive compulsi
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Transcept Pharmaceuticals to Present at BIO Investor Forum
2. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
3. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
4. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
5. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
6. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
8. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
9. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
10. Transcept Pharmaceuticals to Report First Quarter 2009 Results
11. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... Israel , July 21, 2014 ... "Integrity"), developer of the GlucoTrack ® model ... that it has entered, through its wholly-owned subsidiary, ... Wistron Corp, the manufacturing arm of Acer Inc.  ... manufacture and service (on a non-exclusive basis) the ...
(Date:7/21/2014)... JOLLA, Calif. , July 21, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery and ... that the U.S. Food & Drug Administration (FDA) ... single stranded, chemically modified oligonucleotide that binds to ... a therapeutic for the treatment of Alport syndrome, ...
(Date:7/21/2014)... DIEGO , July 21, 2014  An International ... a redesign of its iCH CPAP device, Taiwanese device ... humidification. ResMed (NYSE: RMD ) is the ... for the treatment of sleep-disordered breathing. ... improving designs to reach new levels of comfort, performance ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
... OSLO, Norway, October 31, 2011 Oslo ... oncology. The true strength of the Norwegian cluster lies ... than the ones available to cancer patients today. ... cluster within the field of oncology, dedicated to accelerating ...
... Inc. (ARKRAY) announced today that the GLUCOCARD® Vital and ... (DoD) Uniform Formulary.  The DoD Pharmacy and Therapeutic committee ... 01 Blood Glucose Meters as the first and second ... of service as noted by the Uniform Formulary Beneficiary ...
Cached Medicine Technology:Expanding Norwegian Cluster of Excellence Dedicated to Oncology 2Expanding Norwegian Cluster of Excellence Dedicated to Oncology 3ARKRAY's GLUCOCARD® Vital and 01 Blood Glucose Meters are now on the Department of Defense Uniform Formulary. 2
(Date:7/22/2014)... (PRWEB) July 22, 2014 The ... (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin ... Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast ... major drivers, restraints, challenges, opportunities, current market trends, ... along with the estimates and forecasts of the ...
(Date:7/22/2014)... 22, 2014 Cloud+MD Office 2.0 ... interoperable suite of medical software and services, designed ... providers, that produces “Actionable Information” to help Independent ... Systems and Billing Services optimize a wide range ... Quality, Greater Efficiency, Noticeable Cost Reductions and Better ...
(Date:7/22/2014)... For the past nine years, the LIVESTRONG Foundation ... tandem to help thousands of cancer patients and survivors ... help survivors connect to resources dealing with work discrimination ... to include referrals from PAF to LIVESTRONG to help ... emotional, and financial issues that accompany a diagnosis. ...
(Date:7/22/2014)... 22, 2014 Joining Conquer Paralysis Now as ... the next decade is Paralympic silver medalist and quadriplegic Jennifer ... became a quadriplegic from a spinal cord injury in 1998. ... a cure for paralysis. , “People define cure differently,” French ... something else. We have the image in our minds of ...
(Date:7/22/2014)... Hills, CA (PRWEB) July 22, 2014 ... document management and workflow solutions, announced today their Gold ... 28 – 31 at Mandalay Bay Hotel and Casino ... Sage customers, Sage Summit draws thousands interested in taking ... leaders, learn how to solve business problems and educate ...
Breaking Medicine News(10 mins):Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Cloud-MD Software will soon Receive MU2 Certification 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 3Health News:Paralympian Jen French Announced as Conquer Paralysis Now’s First Champion 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 3
... that it's never too late for a person to start ... ,The researchers particularly taking into consideration the people who ... the exercise need not be of any strenuous nature but ... Dr Dietrich Rothenbacher, an epidemiologist at the University of Heidelberg ...
... variations on how hospitals spend for meals for their ... are spending four times the amounts spent by others.// ... average of ?61 on patients' meals per week as ... to The Scotsman newspaper, there are huge variations reported. ...
... be successfully located with or in pediatric practices, ... Medical Center and the N.C. Chapter of the ... journal Clinical Pediatrics, the researchers said, “With the ... mental health disorders in primary health care settings, ...
... therapy, when used to treat patients who are in ... chances of survival//, say researchers at Rhode Island ... patients over seven years, the median survival rate at ... to 42 months when thermal ablation was followed by ...
... his colleagues working in the laboratory of Dr. Stanley ... that controls// the sensitivity of human cancer cells to ... of research striving towards increased effectiveness of ... in advance of its scheduled August 1 publication date ...
... devised a chip that can be implanted into a patient's arm, ... medical personnel to easily get hold of patients' medical data. , ... have launched the program to test this product, which will go ... ,The chip can be interpreted with the ...
Cached Medicine News:Health News:Exercise Activities Helps To Avoid Heart Ailment 2Health News:Mental Health Providers Can Be Successfully Located With Pediatricians 2Health News:Combination Therapy to the Rescue off Lung Cancer Patients 2Health News:Combination Therapy to the Rescue off Lung Cancer Patients 3
... Shepard Clear Corneal Diamond Knife is a ... Dennis Shepard of Santa Maria, California. This ... Shepard's need for a quality instrument that ... Corneal Surgical technique. Through professional collaboration between ...
The new TRC-NW200 Non-Mydriatic Retinal Camera combines Topcons years of experience in retinal imaging with the latest advances in digital and electronic technology....
... Software is a new approach to practice management, ... face in todays healthcare market. OPIE was created ... who work exclusively in this field, so it ... functional and easy-to-use than anything else available. If ...
... The DioLite 532 laser is ... and pigmented skin lesions such as ... port wine stains, lentigines, dermatosis papulosis ... technology offers unsurpassed reliability, a selection ...
Medicine Products: